There's something awfully tempting about a 10.2% yield. Read More

For MLPs, there is one potentially thorny issue relating to tax reform. Read More

MLP investors are getting most of what they wanted from the tax bill. And the Fed's latest rate hike was largely a snoozer. Read More

There’s a lot going on in the next few weeks. Plus: EPD and Energy Transfer’s commanding positions in the Permian. And Gaming and Leisure Properties’ two main tenants could be about to merge. Read More

MLPs seemed to have lost their correlation with oil ... until this week. Read More

The continuing selloff in MLPs is unwarranted. Read More

Wall Street’s “favorite” short-side analyst takes aim at billionaire Kelcy Warren. Read More

The electoral upset in Virginia could light a fire under Congress to get tax reform done before it faces voters next year. Plus: Our take on ETE and TransCanada's latest results. Read More

The market looks ahead to a new Fed chair and the prospect of sweeping corporate tax reform. Plus: Our take on GLPI and EPD's latest results. Read More

The market is affected by the same seasonal patterns that can make winter such a bummer. Plus: NRZ Residential Investment’s latest results blow past estimates.     Read More

Midstream players have been falling, even though energy prices have been climbing. We examine some of the factors that may be driving this action. Plus: Blackstone has a blowout quarter.   Read More

The midstream giant is slowing its distribution increases to pay for new projects, and investors are right not to be overly bothered. Plus: CNNX in the penalty box and BASF going to seeds. Read More

The Eaton Vance Tax-Advantaged Global Dividend Opportunities has continued to deliver solid gains is trading at a premium to its assets as a result. That won’t last. Read More

Our overseas picks continue to rock despite a stronger dollar and higher bond yields. If energy prices rise, U.S. pipeline stocks could start catching up. Read More

The tussle over Toshiba’s flash memory unit has marked down the stock again, but the future is bright. Read More

The data storage leader holds a strong hand in its tussle over flash memory chips with Toshiba. Its stock is back and has more room to run. Read More

The antiviral drugs champ is paying $12 billion for a promising cancer therapy to jump-start growth. Read More

Economic recovery remains on track despite the presidential corruption scandal, and the stock market has room to run. Read More

EQM’s prospects of delivering an 8% yield on its current price within three years just got brighter. Plus: European shopping trip on tap. Read More

Sinclair is a broadcast empire on the rise, one worth investing in despite its politics. Read More